欢迎访问药物流行病学杂志网站！

设为首页加入收藏

国家科技部中国科技论文统计源期刊

中国科技核心期刊

WHO西太平洋地区医学索引(WPRIM)收录期刊

湖北优秀期刊

《药物流行病学杂志》官方网站与投审稿系统变更通知<点击查看详情>

紫杉醇联合奈达铂治疗卵巢癌的Meta分析

Efficacy and Safety of Paclitaxel Combined with Nedaplatin for Ovarian Cancer: A Meta Analysis

DOI：

中文关键词: 卵巢癌奈达铂紫杉醇 Meta分析

英文关键词:Ovarian cancer Paclitaxel Nedaplatin Meta analysis

基金项目:陕西省重点研发计划项目（编号：2017SF-252）

作者	单位
刘宇凡李琼阁胡斌薛小荣闵慧王静慕羽羽	西安市第四医院药剂科西安 710004

摘要点击次数: 575

全文下载次数: 430

中文摘要:

摘要目的：系统评价紫杉醇联合奈达铂对卵巢癌患者进行治疗的安全性和有效性。方法：计算机检索PubMed、Cochrane Library、Embase、CNKI、WanFang Data、SinoMed数据库，搜集有关紫杉醇联合奈达铂治疗卵巢癌的随机对照试验（RCTs）。检索时限均为建库至2018年4月，由两名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后，采用 RevMan 5.3软件进行分析。 结果：共纳入12 项研究，包括1 219 例患者。Meta分析结果显示，紫杉醇联合奈达铂治疗卵巢癌的总有效率与其他化疗方案相比，差异无统计学意义[OR=1.14，95%CI （0.88，1.48），P=0.16]，但紫杉醇联合奈达铂可提高患者1年生存率[OR=3.37，95%CI（1.47，7.71），P=0.004]和2年生存率[OR=2.24，95%CI（1.27，3.97），P=0.006]，并且该方案显著减少了不良反应的发生率：血小板降低[OR=0.49，95%CI（0.36，0.66），P=0.000 01]、恶心呕吐[OR=0.65，95%CI（0.47，0.89），P=0.007]、外周神经毒性[OR=0.43，95%CI（0.28，0.67），P=0.000 2]及肝功能损伤[OR=0.39，95%CI（0.20，0.77），P=0.006]等不良反应的发生率。 结论：紫杉醇联合奈达铂治疗卵巢癌可延长患者1年及2年生存率且不良反应较轻，受研究数量和质量的限制，结论还需更多高质量的RCTs进行验证。

英文摘要:

ABSTRACT Objective: To systematically evaluate the efficacy and safety of paclitaxel combined with nedaplatin compared with other chemotherapeutics for ovarian cancer. Methods:The databases including PubMed, Cochrane Library, Embase, CNKI, WanFang Data, SinoMed were electronically searched from inception to April 2018 to collect the randomized controlled trials (RCTs) about paclitaxel combining nedaplatin and other chemotherapeutics for ovarian cancer. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then Meta analysis was performed by RevMan 5.3 software. Results:A total of 12 studies were included, involving 1 219 patients. The results of Meta analysis showed that: paclitaxel combining nedaplatin had no significant difference in total effective rate (OR=1.14, 95%CI 0.88 to 1.48, P=0.16), but this chemotherapy regimen significantly increased the 1 year survical rate (OR=3.37, 95%CI 1.47 to 7.71，P=0.004) and 2 year survical rate (OR=2.24, 95%CI 1.27 to 3.97, P=0.006) compared with other chemotherapeutics. The occurrence of lower thrombocyte (OR=0.49, 95%CI 0.36 to 0.66, P=0.000 01) , vomiting adverse reaction (OR=0.65, 95%CI 0.47 to 0.89, P=0.007), Peripheral neurotoxicity (OR=0.43, 95%CI 0.28 to 0.67, P=0.000 2) and liver function damage (OR=0.39, 95%CI 0.20 to 0.77, P=0.006) were also significantly decreased by using paclitaxel combining nedaplatin. Conclusion: Paclitaxel combined with nedaplatin for the treatment of ovarian cancer could reduce the toxic adverse effect while increasing the patient survival rate. The conclusion still need to be verified by more high quality research due to limited sample size and quality in this study.

查看全文查看/发表评论下载PDF阅读器

关闭